Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | CHKA | P35790 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluoride Ion SCHEMBL2453932 | 0.98 | LMNA (0.59) | LMNANPSR1L3MBTL1KDM4ECYP1A2 | |
| Bromide SCHEMBL6981181 | 0.98 | LMNA (0.59) | LMNANPSR1L3MBTL1KDM4ECYP1A2 | |
| Hydrochloric Acid SCHEMBL3196752 | 0.98 | LMNA (0.65) | LMNANPSR1L3MBTL1KDM4ECYP1A2 | |
| Hydrochloric Acid SCHEMBL31272185 | 0.98 | LMNA (0.65) | LMNANPSR1L3MBTL1KDM4ECYP1A2 | |
| Bromide SCHEMBL31255661 | 0.98 | LMNA (0.59) | LMNANPSR1L3MBTL1KDM4ECYP1A2 | |
| SCHEMBL2737208 | 0.79 | LMNA (0.92) | LMNANPSR1L3MBTL1KDM4ECYP1A2 | |
| SCHEMBL28842894 | 0.79 | CALM1 (0.45) | LMNAL3MBTL1KDM4EHTT | |
| Hydrochloric Acid SCHEMBL23611562 | 0.78 | CALM1 (0.44) | LMNAL3MBTL1KDM4EHTT | |
| SCHEMBL13933997 | 0.77 | LMNA (0.58) | LMNANPSR1L3MBTL1KDM4ECYP1A2 | |
| SCHEMBL5293777 | 0.76 | LMNA (0.61) | LMNANPSR1L3MBTL1KDM4ECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| EP-0615855-B1 | Recording sheets containing pyridinium and/or piperazinum compounds | XEROX CORP (US) | 1997-05-14 | — | — | EP | claimed |
| US-20230192614-A1 | METHOD FOR PREPARATION OF TRANS-N-BENZYLOXYCARBONYL-(3-HYDROXY-2-PIPERIDINYL)-2-PROPANONE AS INTERMEDIATE OF HALOFUGINONE | CHENGDA PHARMACEUTICALS CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230192614-A1 | METHOD FOR PREPARATION OF TRANS-N-BENZYLOXYCARBONYL-(3-HYDROXY-2-PIPERIDINYL)-2-PROPANONE AS INTERMEDIATE OF HALOFUGINONE | CHENGDA PHARMACEUTICALS CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-10881653-B2 | Tricyclic compounds and their use in the treatment of cancer | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-01-05 | — | — | US | disclosed |
| US-20200113889-A1 | TRICYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2020-04-16 | — | — | US | disclosed |
| US-7488572-B2 | Image formation method | FUJIFILM CORPORATION (JP) | 2009-02-10 | — | — | US | disclosed |
| US-7488572-B2 | Image formation method | FUJIFILM CORPORATION (JP) | 2009-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192614-A1 | METHOD FOR PREPARATION OF TRANS-N-BENZYLOXYCARBONYL-(3-HYDROXY-2-PIPERIDINYL)-2-PROPANONE AS INTERMEDIATE OF HALOFUGINONE | TALDO1, RPL22, RPS20 | LMNA 533/4885NPSR1 1320/4885L3MBTL1 1388/4885 |
| US-10881653-B2 | Tricyclic compounds and their use in the treatment of cancer | TP53, TOP2A, TK2 | LMNA 714/4885NPSR1 1722/4885L3MBTL1 1302/4885 |
| US-20200113889-A1 | TRICYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | TP53, TOP2A, TK2 | LMNA 714/4885NPSR1 1722/4885L3MBTL1 1302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.